CoChat

A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma

The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.

Abstract

HDAC8 inhibition elicits durable responses to immune checkpoint blockade by improving adaptive immune responses through enhancer reprogramming.

Overview

Integrity signals

Registry

Crossref · 10.1126/scitranslmed.aaz6804

Cites

72 of 72 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 72 references

Cited by

See all 172

Metadata

Authors
Yang, W., Feng, Y., Zhou, J., Cheung, O. K.-W., Cao, J., Wang, J., Tang, W., Tu, Y., Xu, L., Wu, F., Tan, Z., Sun, H., Tian, Y., Wong, J., Lai, P. B.-S., Chan, S. L., Chan, A. W.-H., Tan, P. B.-O., Chen, Z., Sung, J. J.-Y., Yip, K. Y.-L., To, K.-F., & Cheng, A. S.-L.
Affiliations
  • Chinese University of Hong Kong (HK)
  • School of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong SAR 999077, China.
  • University of Hong Kong (HK)
  • Shanghai Jiao Tong University (CN)
  • Shenzhen University (CN)
  • SingHealth (SG)
  • Sun Yat-sen University (CN)
Corresponding author
  • Yang, Weiqin
  • Feng, Yu
  • Zhou, Jingying
  • Cheng, Alfred Sze-Lok
Venue
Science Translational Medicine
Published
2021-04-07
Volume
13
Issue
588
ISSN
  • 1946-6234 (ISSN-L)
  • 1946-6242
OpenAlex
W3198872327
Cited by
172
References
72
Citations by year
2026: 30 · 2025: 45 · 2024: 40 · 2023: 23 · 2022: 27 · 2021: 7
FWCI
9.02
Type
journal article
Language
en
Open access
closed
Locations
  • Science Translational Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • DR-NTU (Nanyang Technological University) (submittedVersion)
Funders
  • Terry Fox Foundation
  • Theme-based Research Scheme (T11-706/18-N)
  • University Grants Committee through the Collaborative Research Fund (C4045-18W)
  • The Focused Innovations Scheme-Scheme B from the Chinese University of Hong Kong (1907309)
  • The Li Ka Shing Foundation
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
Keywords
hepatocellular carcinoma, immune checkpoint blockade, PD-L1 blockade, antitumor immunity, memory T cells, enhancer reprogramming, tumor rechallenge, combination therapy
MeSH terms
Immune Checkpoint Inhibitors, Animals, Carcinoma, Hepatocellular, Histone Deacetylases, Humans, Liver Neoplasms, Repressor Proteins, CD8-Positive T-Lymphocytes, Cell Line, Tumor, Mice, Histone Deacetylase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma. https://app.cochat.ai/papers/10.1126/scitranslmed.aaz6804
The paper
Yang, W., Feng, Y., Zhou, J., Cheung, O. K.-W., Cao, J., Wang, J., Tang, W., Tu, Y., Xu, L., Wu, F., Tan, Z., Sun, H., Tian, Y., Wong, J., Lai, P. B.-S., Chan, S. L., Chan, A. W.-H., Tan, P. B.-O., Chen, Z., . . . Cheng, A. S.-L. (2021). A selective HDAC8 inhibitor potentiates antitumor immunity and efficacy of immune checkpoint blockade in hepatocellular carcinoma. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aaz6804

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.